相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK plus NSCLC
Thomas E. Stinchcombe et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Non-Small Cell Lung Cancer, Version 2.2021 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms
Noriko Yanagitani et al.
CANCER SCIENCE (2020)
Overcoming resistance by ALK compound mutation (I1171S+G1269A) after sequential treatment of multiple ALK inhibitors in non-small cell lung cancer
Ken Takahashi et al.
THORACIC CANCER (2020)
Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
Edyta M. Urbanska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Koutaroh Okada et al.
EBIOMEDICINE (2019)
Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9
Toyoaki Hida et al.
CANCER SCIENCE (2018)
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Satoshi Yoda et al.
CANCER DISCOVERY (2018)
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang et al.
CLINICAL CANCER RESEARCH (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
Hiroyuki Suzuki et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
分享论文
